Kinetics of cytokine gene expression in experimental chagasic cardiomyopathy:: tissue parasitism and endogenous IFN-γ as important determinants of chemokine mRNA expression during infection with Trypanosoma cruzi

被引:158
作者
Talvani, A
Ribeiro, CS
Aliberti, JCS
Michailowsky, V
Santos, PVA
Murta, SMF
Romanha, AJ
Almeida, IC
Farber, J
Lannes-Vieira, J
Silva, JS
Gazzinelli, RT
机构
[1] UFMG, Dept Biochem & Immunol, ICB, BR-31270910 Belo Horizonte, MG, Brazil
[2] FIOCRUZ, CPqRR, Immunopathol Lab, BR-30190002 Belo Horizonte, MG, Brazil
[3] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Microbiol Immunol & Parasitol, BR-14049900 Ribeirao Preto, Brazil
[4] FIOCRUZ, Inst Oswaldo Cruz, Dept Immunol, BR-21045900 Rio De Janeiro, Brazil
[5] Univ Sao Paulo, Dept Parasitol, ICB, BR-05508900 Sao Paulo, Brazil
[6] NIAID, Clin Invest Lab, NIH, Bethesda, MD 20892 USA
基金
巴西圣保罗研究基金会;
关键词
Trypanosoma cruzi; chemokines; macrophages; inflammation;
D O I
10.1016/S1286-4579(00)00388-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We investigated the kinetics of parasite replication, leukocyte migration, and cytokine/chemokine mRNA expression in the heart tissue from animals infected with the Colombiana strain of Trypanosoma cruzi. Cardiac tissue parasitism was noticeable at 15 days, peaked around 30 days and was dramatically reduced at 120 days postinfection (p.i.), Kinetic studies showed that the inflammatory infiltrate was dominated by the presence of alpha beta T CD3(+) CD4(+) CD8(-), alpha beta T CD3(+) CD4(-)CD8(+) lymphocytes and macrophages. The mRNA expression of the monokines IL-1 beta and IL-12(p40) was elevated at 15 days p,i. and controlled at later time points. In contrast, TNF-alpha mRNA was expressed throughout the infection. Interestingly, we found that at 15 and 30 days p.i. cytokine expression was dominated by the presence of IFN-gamma mRNA, whereas at 60 days or later time points the balance of type 1 and type 2 cytokines was switched in favor of IL-4 and IL-10 mRNAs, The chemokine mRNAs encoding JE, MIP-l alpha, MIP-1 beta, KC, and MIP-2 were all mainly expressed at 15 and/or 30 days p,i. and diminished thereafter. In contrast, the expression of RANTES, MIG and IP-10 mRNAs was augmented at 15 days p.i. and persisted at high levels up to 120 days p,i. Taken together, our results indicate that regulation of IFN-gamma and chemokine expression, associated with decreased tissue parasitism, may be largely responsible for the control of inflammation and immunopathology observed in the cardiac tissue of animals infected with ir: cruzi. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:851 / 866
页数:16
相关论文
共 60 条
[1]  
ABRAHAMSOHN IA, 1995, J IMMUNOL, V155, P3955
[2]   Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes [J].
Aliberti, JCS ;
Cardoso, MAG ;
Martins, GA ;
Gazzinelli, RT ;
Vieira, LQ ;
Silva, JS .
INFECTION AND IMMUNITY, 1996, 64 (06) :1961-1967
[3]   LYTIC ANTI-ALPHA-GALACTOSYL ANTIBODIES FROM PATIENTS WITH CHRONIC CHAGAS-DISEASE RECOGNIZE NOVEL O-LINKED OLIGOSACCHARIDES ON MUCIN-LIKE GLYCOSYL-PHOSPHATIDYLINOSITOL-ANCHORED GLYCOPROTEINS OF TRYPANOSOMA-CRUZI [J].
ALMEIDA, IC ;
FERGUSON, MAJ ;
SCHENKMAN, S ;
TRAVASSOS, LR .
BIOCHEMICAL JOURNAL, 1994, 304 :793-802
[4]  
Amichay D, 1996, J IMMUNOL, V157, P4511
[5]   IFN-γ in human Chagas' disease:: Protection or pathology? [J].
Bahia-Oliveira, LMG ;
Gomes, JAS ;
Rocha, MOC ;
Moreira, MCV ;
Lemos, EM ;
Luz, ZMP ;
Pereira, MES ;
Coffman, RL ;
Dias, JCP ;
Cancado, JR ;
Gazzinelli, G ;
Correa-Oliveira, R .
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 1998, 31 (01) :127-131
[6]   Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease [J].
Brener, Z ;
Gazzinelli, RT .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1997, 114 (02) :103-110
[7]  
BRENER Z, 1992, CHAGAS DIS AM TRYPAN
[8]   THE MECHANISMS OF TRYPANOSOMA-CRUZI INVASION OF MAMMALIAN-CELLS [J].
BURLEIGH, BA ;
ANDREWS, NW .
ANNUAL REVIEW OF MICROBIOLOGY, 1995, 49 :175-200
[9]  
Buschenfelde CMZ, 1997, CLIN EXP IMMUNOL, V110, P378, DOI DOI 10.1046/J.1365-2249.1997.4471463.X
[10]  
Camargo MM, 1997, J IMMUNOL, V158, P5890